臨床泌尿器科63巻3号

2009年03月発行

綜説

表在性膀胱癌に対するBCG膀胱内注入療法の作用機序

著者： 小川良雄¹

所属機関： ¹昭和大学医学部泌尿器科

ページ範囲：P.199 - P.206

要旨　BCG（Bacillus Calmette-Guérin）膀胱内注入療法の表在性膀胱癌に対する有効性は確立されているが，その作用機序については不明なところも多い。現時点ではBCGによる，炎症反応，非特異的免疫反応，特異的免疫反応などが継時的に複雑に起こることが推測されており，KT細胞，γδT細胞の関連なども示されている。また，炎症反応が強い症例に効果が高いことが示されている。さらに，TRL（toll-like receptor）やTreg（regulatory T cell）の関与も明らかにされてきている。

参考文献

. J Bacteriol 178：1274-1282, 1996

2）Pearl R：Cancer and tuberculosis. Am J Hyg 9：97-100, 1929

3）Morton D, Eilber FR, Malmgren RA, et al：Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68：158-163, 1970

4）Zbar B, Bernstein ID and Rapp HJ：Suppression of tumor growth at the site of infection with living Bacillus Calmettee-Guérin. J Natl Cancer Inst 46：831-839, 1971

5）Zbar B and Rapp HJ：Immunotherapy of guinea pig cancer with BCG. Cancer 34：1532-1540, 1974

6）Morales A, Eidinger D and Bruce AW：Intracavitary bacillus Calmettee-Guérin in the treatment of superficial bladder tumors. J Urol 116：180-183, 1976

7）Kavoussi LR, Brown EJ, Ritchey JK, et al：Fibronectin-mediated Calmettee-Guérin bacillus attachment to murine bladder mucosa：requirement for the expression of an antitumor response. J Clin Invest 85：62-67, 1990

8）Zhao W, Schorey JS, Bong-Mastek M, et al：Role of a bacillus Calmettee-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86：83-88, 2000

9）池田のりこ，戸井田一郎，山田博之，他：Bacillus Calmettee-Guérin（BCG）と膀胱癌細胞のinteraction．Biotherapy 10：879-884，1996

10）Ludwig AT, Moore JM, Luo Y, et al：Tumor necrosis factor-related apoptosis-inducing ligand：a novel mechanism for Bacillus Calmettee-Guérin-induced antitumor activity. Cancer Res 64：3386-3390, 2004

11）Mehmut M, Takeda K, Abe M, et al：Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmettee-Guérin treatment. Urol Int 75：80-87, 2005

12）Janeway CAJ and Medzhitov R：Innate immune recognition. Annu Rev Immunol 20：197-216, 2002

. Tuberculosis（Edinb） 83：91-97, 2003

14）Suttmann H, Riemensberger J, Bentien G, et al：Neutrophil granulocytes are required for effective Bacillus Calmettee-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 66：8250-8257, 2006

15）de Boer EC, de Jong WH, van der Meijden AP, et al：Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer：a flow cytofluorometric analysis. Urol Res 19：45-50, 1991

16）Saint F, Patarda JJ, Irania J, et al：Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 57：617-621, 2001

17）Böhle A, Gerdes J, Ulmer AJ, et al：Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144：53-58, 1990

18）Brandau S, Riemensberger J, Jacobsen M, et al：NK cells are essential for effective BCG immunotherapy. Int J Cancer 92：679-702, 2001

19）Brandau S, Suttmann H, Riemensberger J, et al：Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells. Clin Cancer Res 6：3729-3738, 2000

20）de Reijke TM, Vos PCN, Bevers RFM, et al：Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmettee-Guérin. Urol Res 21：349-352, 1993

21）斎藤文匡，高島　徹，呉　聖哲，他：膀胱移行上皮癌に対するBacillus Calmette-Guérinの免疫学的作用機序の研究血清及び尿中のTNF-α，IL-2の変動について．日泌尿会誌 85：466-472，1994

22）Esuvaranathan K, Alexandroff AB, McIntyre M, et al：Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154：572-575, 1995

23）Thalmann GN, et al：MEDICINE Publishing Foundation, 1997

24）Naoe M, Ogawa Y, Takeshita K, et al：Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and γδT cells. Int J Urol 14：532-538, 2007

25）Suttmann H, Jacobsen M, Reiss K, et al：Mechanisms of bacillus Calmettee-Guérin-mediated natural killer cell activation. J Urol 172：1490-1495, 2004

26）Brandau S, Riemensberger J, Jacobsen M, et al：NK cells are essential for effective BCG immunotherapy. Int J Cancer 92：697-702, 2001

27）Brandau S, Suttmann H, Riemensberger J, et al：Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmettee-Guérin-activated killer cells. Clin Cancer Res 6：3729-3738, 2000

28）Märten A, von Lilienfeld-Toal M, Büchler MW, et al：Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 119：2359-2365, 2006

29）Gober HJ, Kistowska M, Angman L, et al：Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197：163-168, 2003

by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116：94-99, 2005

31）Beatty JD, Islam S, North ME, et al：Urine dendritic cells：a noninvasive probe for immune activity in bladder cancer? BJU Int 94：1377-1383, 2004

32）Yamaguchi T and Sakaguchi S：Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16：115-123, 2006

33）Loskog A, Ninalga C, Paul-Wetterberg G, et al：Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol 177：353-358, 2007

34）Brandau S：Local and systemic immune suppression in bladder cancer. J Urol 177：12-13, 2007